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Healthcare workers (HCWs) are at increased risk of contracting 
infectious diseases owing to workplace exposure.[1,2] High 
disease prevalence and reduced investment in and availability of 
adequate safety measures place HCWs in developing countries at 
disproportionate risk compared with their counterparts in high-
income countries.[3] HCWs in these settings are at particular risk of 
contracting tuberculosis and blood-borne pathogens such as HIV, 
hepatitis B and hepatitis C.[1,4] An important mechanism of exposure 
to blood-borne pathogens is accidental needlestick injury (NSI).
The incidence of NSI varies across settings, and significant under-
reporting to occupational and public health authorities affects the 
validity of estimates. Studies from South Africa (SA) place the 
incidence of NSI between 24% in primary care nurses and up to 
69% among junior doctors per annum.[5,6] Risk factors for sustaining 
an NSI vary depending on the context. Less-experienced staff and 
those who have not received training in universal precautions 
have consistently been found to be at increased risk of sustaining 
an NSI. [7-9] In developed countries, the evidence indicates that 
doctors are at higher risk of NSI than nurses.[10] However, given the 
clinical load placed on mid-level HCWs in low- and middle-income 
countries, this is not necessarily the case in developing countries.[7]
Given their risk and severity, the most important potential 
consequences of an NSI are acquiring HIV or hepatitis B or C. The 
transmission probability following an occupational NSI is 6 - 30% 
for hepatitis B and up to 2.83% for HIV.[11,12] Globally, 4.4% of HIV, 
37% of hepatitis C and 39% of hepatitis B infections in HCWs are 
attributable to NSI.[13] Furthermore, HCWs commonly experience a 
range of psychological symptoms following occupational exposure to 
blood or body fluids.[14] NSIs also impose economic costs on health 
systems and society.[15-20]
Training in universal precautions and adoption of safety-
engineered devices (SEDs) are two key interventions that have been 
shown to reduce NSIs.[21-25] On pooled analysis of five studies, Harb 
et al.[22] reported an effectiveness of 46% (relative risk (RR) 0.54, 
95% CI 0.41 - 0.71) for SEDs in reducing NSIs among HCWs.[22] 
Similarly, Tarigan et al.[23] estimated that SEDs were 49% (RR 0.51, 
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Background. Healthcare workers (HCWs) are at increased risk of contracting various communicable diseases. Needlestick injuries (NSIs) 
are a common mechanism of exposure. Training in basic universal precautions and utilisation of safety-engineered devices (SEDs) are 
interventions known to reduce the risk of NSI.
Objectives. To assess the cost-utility of SEDs v. a training programme in universal precautions (TP) v. a combination strategy to reduce 
NSIs among South African HCWs.
Methods. A Markov model comparing SEDs v. a TP v. a combination strategy against current practice was developed. A hypothetical cohort 
of HCWs working in the SA public sector was followed from a payer’s perspective for a period of 45 years, and discounted costs and benefits 
were assessed. Data were obtained from the National Department of Health, suppliers and published literature. One-way and probabilistic 
sensitivity analysis was conducted.
Results. Over the study time horizon, our model estimated that 2  209, 3 314 and 4 349 needlestick injuries per 1 000 HCWs could 
be prevented if a TP, SEDs or a combination strategy, respectively, was adopted compared with current practice. All three candidate 
interventions were cost-effective at a willingness to pay (WTP) of one times the gross domestic product per capita (USD6 483.90/quality-
adjusted life-year (QUALY) gained). SEDs as a stand-alone intervention was dominated by a combination strategy. Compared with current 
practice, the incremental cost-effectiveness of training was USD32.90/QALY v. USD432.32/QALY for SEDs and USD377.08/QALY for a 
combination strategy. Results were sensitive to the effectiveness of the interventions. Probabilistic sensitivity analysis showed that at a WTP 
of USD6 483.90/QALY gained, a combination strategy would be cost-effective 95.4% of the time.
Conclusions. A combination strategy in which both SEDs and a TP are adopted is preferred.
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95% CI 0.40 - 0.64), training 44% (RR 0.66, 95% CI 0.50 - 0.89), and a 
combination of training and SEDs 62% (RR 0.38, 95% CI 0.28 - 0.50) 
effective in reducing NSIs among HCWs. In contrast, a fourth review 
found only low-quality evidence to suggest that SEDs may reduce 
NSIs, but moderate (statistically non-significant) evidence that they 
could increase blood splashes by 60% (RR 1.6, 95% CI 0.08 - 2.36).[24]
The few studies that have attempted to assess the cost-effectiveness 
of SEDs or training in reducing NSIs were either single-centre 
studies with limited cost perspectives[26-29] or did not undertake any 
uncertainty analysis.[27] With these limited cost perspectives, lack 
of methodological robustness and the fact that these studies were 
all done in high-income settings with a low HIV prevalence, there 
is currently insufficient evidence to guide decision-making on the 
adoption of SEDs and training programmes (TPs) in SA.
Objectives
To assess the cost-utility of SEDs, a basic universal precautions TP 
or a combination of both interventions v. current practice in the SA 
public healthcare sector.
Methods
Ethics review was not required for this study, as it did not require 
the collection or analysis of any primary data. Findings are reported 
in compliance with the Consolidated Health Economic Evaluation 
Reporting Standards (CHEERS).[30]
Study setting
SA, a middle-income country with a gross domestic product (GDP) per 
capita in 2014 of USD6 483.90, has the largest HIV-positive population 
in the world, with an estimated prevalence among the general population 
of 12.2%.[31,32] There are no national policies or regulations aimed at 
reducing sharps injuries in HCWs. However, current SA HIV guide-
lines provide for triple-therapy post-exposure prophylaxis (PEP) in cases 
where HCWs are exposed or potentially exposed to HIV.[33]
Study design
A decision analytical Markov model with 1-year cycles was developed 
to assess the cost-utility, from a public payer perspective, of current 
practice v.: (i) a stand-alone biennial universal precautions TP; 
(ii)  adoption of SEDs as a stand-alone intervention; or (iii) a TP 
and SEDs in combination. A hypothetical HIV-uninfected cohort of 
HCWs, defined as doctors and nurses joining the SA public sector in 
2015, transition through seven possible Markov states over a 45-year 
time horizon from the age of 20 as new entrants to the workforce 
(in 2015) to the retirement age of 65. Medical and nursing students 
in SA commence clinical rotations, and therefore become at risk to 
exposure, during their second or third year of study.
In this analysis we only included devices utilised for: (i) initiating 
a peripheral intravenous infusion; (ii) delivering an injection 
(intramuscular and/or subcutaneous); or (iii) phlebotomy. Based on 
our estimates, only 7.2% (in terms of volume) of devices purchased 
by the public sector in 2015 were SEDs; however, our epidemiological 
data precede 2015 and reflect a much lower market share of SEDs. 
Training was defined as basic training in universal precautions. To 
our knowledge, with the exception of one tertiary academic hospital, 
there is currently no routine training on universal health precautions 
in the public sector. We therefore assumed the current practice (base-
case) scenario to have no training and 0% coverage in SEDs.
Transition probabilities
Transition probabilities are summarised in Table 1. Self-reported 
incidence data of NSIs suffer from significant under-reporting, so 
Table 1. Cohort and population characteristics and transition probabilities
Characteristic Base case Sensitivity analysis Source
Age (years) 20 - 65 - Assumption
Time horizon (years) 45 - Assumption, working life
Cost perspective Public payer - Assumption
Cohort composition, %
Doctors 13.2 - [44,45]
Nurses 86.8 - [46,47]
Transition probabilities*
Annual attrition rate 0.031 0.024 - 0.038 [44]
Annual probability of NSI [5,6,34-36]
Year 1 0.69 0.600 - 0.78 
Year 10 0.50 0.270 - 0.73
Year 20 0.37 0.280 - 0.47
Year 30 0.22 0.002 - 0.53
Year 45 0.10 0.000 - 0.28
Prevalence of HIV, % 30 Beta [37-40]
HIV transmission 0.0023 Beta [41]
Effectiveness PEP 0.81 0.43 - 0.94 [42,43]
HIV progression
Asymptomatic to symptomatic 0.32 [48]
Symptomatic to AIDS 0.20 [48]
Annual mortality rate (probability*)
Asymptomatic HIV 0.0148 [49]
Symptomatic HIV 0.0169 [49]
AIDS 0.21 [49]
NSI = needlestick injury; PEP = post-exposure prophylaxis.
*1 = absolute certainty an event will occur, 0 = absolute certainty an event will not occur.
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we did not use any hospital surveillance or administrative data in 
estimating the probability of NSIs. All epidemiological input data for 
the model were obtained from published literature. An important 
determinant in the probability of sustaining an NSI and transitioning 
from the ‘well’ to the ‘NSI’ state is work experience (see Fig. 1 for the 
Markov model and the appendix (available from the corresponding 
author on request, email pieter.dejager@wits.ac.za) for the transition 
probability matrix).[7-9] To account for work experience, transition 
to the NSI state was time-dependent and based on pooled estimates 
from available SA epidemiological studies (see appendix for pooled 
estimate results).[5,6,34-36] Linear interpolation was used to estimate 
probabilities between years. After sustaining an NSI, transition 
back to the ‘well’ state or progression to the ‘HIV-exposed’ state 
occurred as a function of the estimated HIV prevalence rates found 
in outpatient department and hospitalised patients in SA. Based on a 
pooled estimate of available studies, we estimated this to be 30% (95% 
CI 15 - 47)[37-40] (see appendix for additional details).
Transition probability from ‘HIV-exposed’ to ‘HIV-infected’ 
was obtained from a meta-analysis estimating the probability of 
seroconversion following an NSI where the source patient is HIV-
infected (0.23%).[41] In our model we assumed that there is universal 
access to timely PEP for all exposed HCWs, and we therefore adjusted 
the probability of seroconversion by the efficacy of PEP (81%).[42,43]
Transition from ‘HIV asymptomatic’ to ‘HIV symptomatic’ and 
finally ‘AIDS’ was based on epidemiological estimates of transition 
from SA.[49] It was possible to transition from the ‘well’, ‘NSI’ and 
‘HIV-exposed’ states to the absorptive state ‘exit’, the probability of 
which was taken to be the estimated annual mean attrition rate for 
doctors (3.8%) and nurses (2.4%) from the public sector.[44,46] In 
contrast, transition from ‘HIV symptomatic’, ‘HIV asymptomatic’ 
and ‘AIDS’ to the saturation state ‘exit’ was taken to be the mortality 
rate for these groups[49,50] plus the background attrition rate.[44,46] Fig. 1 
provides a schematic summary of the Markov model.
Costs
The cost perspective of this study is that of the public payer, namely 
the National Department of Health (NDoH), as the purchaser of 
devices and primary employer of all HCWs in the public sector. 
All cost data were adjusted for inflation and converted to US 
dollars to allow for international comparison, and are reported in 
2015 terms. [51] Costs were attributed to HCWs to obtain cost per 
HCW estimates. It is estimated that there were ~106  822 doctors 
(13.2%) and nurses (86.8%) employed in the public sector in SA in 
2015. [44-46,52] In the public sector, HCWs are salaried workers with 
wage scales published annually by the Department of Public Service 
Administration.[53] From these data, we estimated that the weighted 
mean daily wage of doctors and nurses in 2015 was USD101.14. Wage 
data were included in the model to account for the opportunity cost 
of training and absenteeism costs resulting from HIV exposure and 
subsequent side-effects of taking PEP.
Cost items and quantities required in the management of HIV PEP 
were identified through the review of current clinical management 
guidelines adopted in SA.[54] Laboratory costs were obtained from 
the National Health Laboratory Service (NHLS), the sole laboratory 
service provider for the public sector (NHLS State Price List 2015, 
obtained from the NHLS). For pharmaceutical costs, single-exit prices 
for antiretroviral drugs were obtained from the NDoH.[55] Other PEP 
programme costs included in the analysis were pre- and post-test 
counselling and occupational health follow-up visits. Treatment costs 
for HIV were obtained from the literature and differentiated between 
asymptomatic, symptomatic and AIDS care. [48] For our analysis, in 
line with World Health Organization (WHO) recommendations, 
we assumed that all HCWs who seroconvert are initiated on highly 
active antiretroviral treatment at the time of diagnosis, regardless of 
CD4+ count.[56]
Obtaining estimates from both suppliers and the NDoH, we 
triangulated cost data for SED and non-SED devices. Devices are 
purchased on a tender system by provincial departments of health, so 
there is heterogeneity in the pricing of various items across provincial 
administrations. We estimated the total volume for each category of 
devices (i.e. devices utilised for initiating a peripheral intravenous 
infusion, delivering an injection, or used for phlebotomy) purchased 
by the public sector in 2015 stratified by SED and non-SED. We 
obtained low and high price estimates for each device category for 
both SED and non-SED devices. From these data we calculated the 
total cost for each category under two scenarios: zero SED coverage 
and 100% SED coverage. By applying the estimated number of HCWs 
employed in the public sector in 2015, we calculated the cost per 
HCW for each device category and each scenario. Training costs were 
estimated from current training courses available in SA. Under the 
training intervention, we assumed that HCWs would attend biennial 
full-day training on basic universal precautions to be provided 
on-line. On-line courses are available and are undergoing further 
refinement by SA universities.[59] Table 2 provides a summary of the 
cost components included in the model.
Effectiveness
Benefits accrued under each scenario were measured in quality-
adjusted life-years (QALYs). QALYs are utility-based composite 
measures of morbidity and mortality associated with given health 
states and allow for comparability across studies and health outcomes. 
We assumed the ‘well’ state to be associated with perfect health 
and therefore assigned a utility score of 1. No studies were found 
that reported QALYs for NSI, but this event is typically associated 
with localised pain and psychological distress.[60] We therefore 
assigned a conservative, near-perfect level of health (QALY 0.98, 
sensitivity range  0.95 - 1) to the ‘NSI’ health state and assessed 
this assumption in both the univariate and probabilistic sensitivity 
analysis. Utility scores for being HIV-exposed had previously been 
estimated through expert consultation as reported by Haddix et al.[61] 
QALYs for asymptomatic, symptomatic and advanced (AIDS) HIV 
were obtained from a meta-analysis by Tengs and Wallace.[62]
A recent systematic review and meta-analysis by Tarigan et al.[23] 
estimated the pooled effectiveness of SEDs, training and combined 
training and SEDs in reducing NSIs among healthcare workers. [23] 
Well                                              NSI                                  HIV exposed
HIV asymp.
HIV symp.
AIDS
Exit
Fig. 1. Schematic summary of the Markov model. (NSI = needlestick injury; 
asymp. = asymptomatic; symp. = symptomatic.)
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Table 2. Economic model inputs (costs expressed in 2015 USD)
Base case Sensitivity analysis Source
Cost component
Discount rate, % 3 0 - 6 [57]
USD conversion 12.54 - [58]
Opportunity costs
Weighted mean daily wage, USD 101.14 Log-normal [53]
Absentee days, n 3.5 0 - 7 Assumption
Training time, n days per annum 0.5 - Assumption
HIV occupational exposure costs, USD
HIV ELISA 47.71 - †
Serum creatinine 26.24 - †
PEP ARV costs* 103.41 Log-normal [55]
Pre- and post-test counselling 4.00 - [53]
Occupational health consult 15.95 - [53]
Cost of HIV treatment, USD
Asymptomatic 416.78 Log-normal [48]
Symptomatic 421.28 Log-normal [48]
AIDS 455.07 Log-normal [48]
Intervention costs per HCW, USD
Non-SED 51.59 Log-normal ‡
SED 274.89 Log-normal ‡
TP 23.92 Log-normal [59]
ELISA = enzyme-linked immunosorbent assay; PEP = post-exposure prophylaxis; ARV = antiretroviral; HCW = healthcare worker; SED = safety-engineered device;  
TP = training programme; NHLS = National Health Laboratory Service.
*USD103.41 is the total cost of 28 days of treatment as per national guidelines (tenovofir 300 mg/d, emtricitabine 200 mg/d plus raltegravir 400 mg twice a day).
†NHLS State Price List 2015, obtained from the NHLS.
‡These costs were obtained from suppliers.
Table 3. Utility scores for various health states
Health state QALY
Sensitivity
SourceStandard deviation Probability distribution
Well 1 0 Assumed
NSI 0.98 0.014 Beta Assumed 
HIV-exposed 0.95 0.021794 Beta [61]
HIV asymptomatic 0.88 0.19 Beta [62]
HIV symptomatic 0.822 0.224 Beta [62]
AIDS 0.64 0.0735 Beta [62]
QALY = quality-adjusted life-year; NSI = needlestick injury. 
Table 4. Effectiveness of interventions
Interventions Base case, % reduction Sensitivity, uniform distributions Source
Training 0.34 0.11 - 0.5 [23]
SEDs 0.49 0.36 - 0.6 [23]
SEDs and TP 0.62 0.5 - 0.72 [23]
PEP 0.81 0.43 - 0.94 [42,43]
SEDs = safety-engineered devices; TP = training programme; PEP = post-exposure prophylaxis. 
Table 5. Cost-effectiveness of three intervention strategies compared with current practice to reduce NSIs among SA public  
sector HCWs
Intervention
Cost per HCW 
(USD)
Incremental cost 
(USD)
Effectiveness 
(QALYs) 
Incremental 
effectiveness 
(QALYs)
ICER (USD/
QALY) CE
Current practice 1 163.29 - 15.3 - - 76.90
TP only 1 247.64 84.34 17.69 2.56 32.90 70.53
SEDs only 3 151.17 1 987.87 19.73 4.60 432.32 159.75
SEDs and TP 3 619.04 2 455.74 21.64 6.51 377.08 167.24
NSI = needlestick injury; SA = South African; HCWs = healthcare worker; QALYs = quality-adjusted life-years; ICER = incremental cost-effectiveness ratio; CE = cost-effectiveness;  
TP = training programme; SEDs = safety-engineered devices.
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The pooled estimates are based on 17 studies, 16 of which were 
before-and-after in design, while one was a randomised controlled 
trial.[25] The effectiveness of HIV PEP was obtained from two case-
control studies.[42,43] Tables 3 and 4 provide a summary of the utility 
scores and effectiveness data, respectively.
Analysis
We developed and analysed our decision analytical Markov model 
in TreeAge Pro 2015 (TreeAge Software, USA). Costs and benefits 
accruing to each Markov state under each of the four scenarios under 
consideration were calculated by conducting a cohort simulation 
(N=10  000). From this analysis we estimated the number of NSI 
and HIV exposure events under each scenario over the 45-year time 
horizon as well as the cumulative probability of contracting HIV 
due to NSIs. Following WHO guidelines, all costs and benefits were 
discounted at 3% and varied between 0% and 6% in the sensitivity 
analysis.[57] To avoid overestimating the final cycle’s lifetime, half-
cycle corrections were applied to all costs and benefits. Incremental 
cost-effectiveness ratios (ICERs) were calculated to assess the cost-
effectiveness of each intervention scenario with current practice. 
There are currently no willingness to pay (WTP) thresholds for SA, 
so we adopted WHO guidelines to assess cost-effectiveness.[63] The 
per capita GDP for SA in 2014 was USD6 483.90 and was taken as the 
cost-effectiveness threshold.[63,64]
In order to assess the robustness of our estimates, we conducted 
one-way and probabilistic sensitivity analysis. One-way sensitivity 
analysis was undertaken to assess the effects of biasing input 
parameters to upper and lower limits. Multi-way Monte Carlo 
simulation (probabilistic sensitivity analysis) consisting of 10  000 
simulations in which all input parameters were varied simultaneously 
as a function of their underlying probability distributions was 
undertaken (see appendix for additional details).
Results
Base case
Both SEDs and training as stand-alone interventions or in 
combination improve health outcomes in HCWs by reducing the 
number of NSI events, HIV exposures and the lifetime probability 
of contracting HIV due to NSIs. Over a 45-year working life, it is 
estimated that 2 209, 3 314 and 4 349 NSI per 1 000 HCWs would 
be prevented if a TP alone, SEDs alone, or training and SEDs in 
combination, respectively, were to be adopted in the public sector 
compared with current practice. This translates into 672, 1 009 and 
1 325 HIV exposure events averted and reductions in the cumulative 
probability of seroconversion from 0.91% (current practice) to 0.66% 
(TP), 0.53% (SEDs) and 0.41% (SEDs and TP).
All three intervention strategies were more costly than current 
practice (Table 5 and Fig. 2). The average annual discounted cost 
per HCW under current practice was estimated at USD1 163.29 
compared with USD1  247.64, USD3 151.17 and USD3  619.04 per 
HCW for a stand-alone TP, SEDs alone or training and SEDs in 
combination, respectively. Compared with current practice, a stand-
alone TP would increase discounted QALYs by 2.56 at an additional 
discounted cost of USD84.34. Training was found to be a highly 
cost-effective intervention, with an ICER of USD32.90/QALY gained. 
Although cost-effective, the SEDs-only strategy was dominated by a 
combination strategy of both SEDs and training. SEDs alone were 
estimated to increase discounted QALYs by 4.90 at an additional 
discounted cost of USD1 987.87 and an ICER of USD432.32/QALY 
gained.
It is estimated that adopting a combination strategy of both 
SEDs and training would increase discounted QALYs by 6.51 
compared with current practice at an additional discounted cost of 
USD2 455.74. Therefore, under the base case, SEDs in combination 
with a TP was the preferred intervention with an ICER of USD377.08 
per QALY gained.
Sensitivity analysis
The effectiveness of SEDs, training and training in combination 
with SEDs were the most important variables on univariate sensivity 
analysis, impacting on the ICERs for each strategy. Net benefit one-
way sensitvity analysis was used to take account of effectiveness, 
cost and WTP as the input variable changes.
Although the effectiveness of training, SEDs and a combination 
of training and SEDs impacted on the net benefit, the impact was 
not sufficient to change the strategy. Varying the effectiveness of 
each intervention strategy within plausible ranges, a combination 
strategy of both SEDs and training remains the strategy of choice at 
a WTP threshold of USD6 483.90 per QALY gained (see appendix).
Results from the Monte Carlo probabilistic sensitivity analysis, 
whereby all the uncertainty captured by the model inputs was 
assessed simultaneously, are reported in Fig. 3. A combination 
strategy is prefered at a WTP threshold of USD6 483.9 per QALY 
gained, where it would be a cost-effective strategy 95.4% of the 
time.
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Discussion
Our study assessed the cost-utility of three strategies, compared with 
current practice, aimed at reducing NSIs among HCWs in a high 
HIV prevalence setting. We found that a combination strategy of 
adopting both SEDs and training in universal precautions would be 
the preferred strategy, with an ICER of USD377.08 per QALY gained. 
This is significantly lower than SA’s per capita GDP (USD6 483.90), 
making it a highly cost-effective option in reducing NSIs among 
doctors and nurses working in the public sector.
A combination strategy would reduce the number of NSIs and 
exposure events and reduce the number of occupational HIV cases. 
Prüss-Üstün et al.[13] estimated that globally there are 1 000 (range 
200 - 5 000) cases of HIV per year in HCWs due to NSI, with 720 
(range 130 - 3 510) occurring in Africa.[13] Over a 45-year time 
horizon, we found that a combination strategy would reduce the 
cumulative probability of acquiring HIV from NSI by 54.9% (from 
0.91% to 0.41%). Based on our model estimates, we calculate that there 
are, under current practice, ~20 cases of HIV per annum in HCWs 
in SA and that this could be reduced to nine cases if a combination 
strategy were to be implemented. There are no published statistics 
available in SA on the number of occupationally acquired cases of 
HIV infection in HCWs. Given that there were 56 confirmed and 
136 possible cases of occupationally acquired HIV cases in US HCWs 
between 1985 and 1999 and it is estimated that in Europe there are 
7 cases per annum,[13] our calculation of 20 cases per year is probably 
an under-estimation due to our model assumption that there is 100% 
access and compliance to timely diagnostics and PEP.
This is the first study to assess the cost-effectiveness of SEDs in a 
developing country context. All the previous studies were conducted 
in single centres in high-income countries, with limited costing 
perspectives and no utilisation of uncertainty and sensitivity analysis 
and expressed effectiveness as cost per NSI averted, thus limiting 
the comparability of previous findings with ours.[26-29] Nevertheless, 
we estimate that the cost per NSI averted would be USD38.18, 
USD599.84 and USD564.67 for training alone, SEDs alone or a 
combination strategy, respectively. Previous estimates of the cost-
effectiveness of SEDs from the USA have ranged from USD789 to 
USD2 571, and in Europe it has been calculated that savings would 
range from EUR2.65 to EUR869.79 per NSI averted. [26-29] Our 
estimates, although not directly comparable, fall within the ranges 
estimated in the European study, but are lower than those from the 
USA.
Study limitations
Our study had a number of limitations. First, we did not take 
account of all the costs and consequences of NSI. To make our 
model more manageable, we did not consider hepatitis B or C, 
even though together with HIV they are the most common blood-
borne pathogens transmitted through NSI – with a prevalence of 
>8% in the general population, hepatitis B is endemic in SA.[65] 
Further, we only included doctors and nurses from the time they 
are students in our analysis, but other HCWs such as laboratory 
technicians and cleaning staff are also at risk of NSI. In settings 
with inadequate medical waste management, communities are 
also at risk of sustaining NSI. Therefore, excluding the costs of 
other infectious diseases and HCWs or communities affected by 
NSI from our model, we have probably underestimated the true 
cost-effectiveness of the interventions. Second, we assumed that 
HIV prevalence in the source population would remain constant 
over the 45-year period and varied it within a constant range in 
the sensitivity analysis. The age-standardised prevalence of HIV 
has stabilised in SA, increasing by only 0.002 per 100 000 between 
2005 and 2015,[31] so this assumption will probably not affect the 
model estimates greatly. Third, the evidence on the effectiveness 
of the interventions was largely based on observational studies. We 
took estimates from the most recent and complete meta-analysis 
on the effectiveness of SEDs, training and a combination of the two 
strategies and varied these in the sensitivity analysis. Fourth, there 
are limited epidemiological studies investigating the incidence of 
NSI in SA. We searched the literature and pooled the estimates from 
all available studies, stratified estimates based on work experience 
and varied these estimates in the sensitivity analysis. Finally, there 
are no available utility estimates for NSI events per se, so we assumed 
NSI to be associated with a QALY of 0.98 and varied this assumption 
in the sensitivity analysis.
Highlights
• HCWs are at increased risk of contracting infectious diseases, 
including HIV secondary to accidental NSI. Although SEDs and 
training in universal precautions are known to reduce NSIs, it is 
not known whether these would be cost-effective interventions in 
a middle-income country with a high HIV burden.
• Our economic evaluation shows that a combination strategy that 
includes both the adoption of SEDs and a biannual TP for HCWs 
in SA’s public sector would be cost-effective from a public payer’s 
perspective.
• Our findings provide policy guidance on an important yet often 
overlooked aspect of health policy in SA, the health of HCWs.
Conclusions
Our study shows that a combination strategy in which both SEDs and 
a basic universal precautions TP are adopted is the preferred strategy 
to reduce NSIs in HCWs in SA’s public sector. Given the lack of 
policy on the prevention of NSI in SA, our study provides important 
evidence to inform decision-making. As a starting point the SA 
NDoH is currently engaged in policy processes on occupational 
health for health workers in respect of HIV and tuberculosis, and our 
study is very pertinent to that process, especially in advocating for the 
inclusion of a policy tenant on NSI prevention. Since procurement in 
SA may be centralised in some provincial departments of health, the 
authors would encourage improved communication with infection 
prevention and control and occupational health and safety. Finally, 
our findings or model may also be applicable to other settings with 
similar levels of economic development and where there is a high 
burden of HIV.
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